Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Launched by TELIK · Jun 18, 2010
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • relapsed or refractory disease
- • histologically or cytologically confirmed disease
- • characteristic immunophenotypic profiles
- • measurable disease (for lymphoma patients)
- • ECOG performance status of 0-2
- • adequate liver and kidney function
- • adequate bone marrow reserves
- • ineligible or unwilling to undergo autologous stem cell transplantation
- Exclusion Criteria:
- • failure to recover from any major surgery within 4 weeks of study entry
- • pregnant or lactating women
- • women of child-bearing potential not using reliable and appropriate contraception
- • routine prophylactic use of G-CSF required within 2 weeks of study entry
- • Grade 3 or higher peripheral neuropathy
- • history of hepatitis B virus or HIV
- • central nervous system or meningeal involvement by lymphoma or multiple myeloma
About Telik
Telik, a biopharmaceutical company, focuses on the discovery and development of innovative therapies for cancer and other serious diseases. Leveraging its proprietary drug development platform, Telik aims to identify and advance novel compounds that target critical pathways in tumor biology. With a commitment to scientific excellence and patient-centric approaches, the company strives to bring transformative treatments to market, addressing unmet medical needs and improving the quality of life for patients worldwide. Through rigorous clinical trials and collaborations, Telik is dedicated to fostering advancements in therapeutic options and enhancing outcomes in oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Brunswick, New Jersey, United States
Patients applied
Trial Officials
Joseph Bertino, MD
Principal Investigator
Rutgers Cancer Institute of New Jersey
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials